CA3220228A1 — Ketamine in the treatment of behavioural addictions
Assigned to Awakn Ls Europe Holdings Ltd · Expires 2022-12-01 · 3y expired
What this patent protects
Disclosed are pharmaceutical compositions of ketamine and methods of their use in treatment, such as in ketamine-assisted psychotherapy (KAP), including both single KAP sessions and KAP treatment regimes, to treat patients with behavioural addictions, such as gambling disorder, g…
USPTO Abstract
Disclosed are pharmaceutical compositions of ketamine and methods of their use in treatment, such as in ketamine-assisted psychotherapy (KAP), including both single KAP sessions and KAP treatment regimes, to treat patients with behavioural addictions, such as gambling disorder, gaming disorder, compulsive sexual behaviour disorder, and binge eating disorder, among others.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.